DiamiR Biosciences Corp. (DIMR)
DiamiR Biosciences was planning to go public, but the IPO was withdrawn on Jul 14, 2025.
Stock Price: Pending
IPO price not available yet
DiamiR Biosciences Revenue
DiamiR Biosciences had revenue of $1.32M in the twelve months ending February 29, 2024. In the fiscal year ending May 31, 2023, DiamiR Biosciences had annual revenue of $1.13M, down -21.71%.
Revenue (ttm)
$1.32M
Revenue Growth
-21.71%
P/S Ratio
n/a
Revenue / Employee
$264,193
Employees
5
Market Cap
n/a
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2023 | 1.13M | -312.86K | -21.71% |
| May 31, 2022 | 1.44M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDIMR News
- 1 year ago - Diagnostic test developer DiamiR Biosciences files for a $7 million IPO - Renaissance Capital
- 1 year ago - DiamiR Biosciences IPO Registration Document (S-1) - SEC